◆ 会议时间：2023年9月9-12日
◆ 会议地点：新加坡（Singapore）

◆ 会议简介：

2023年IASLC世界肺癌大会(WCLC2023)将于2023年9月9-12日在新加坡举行，会议由国际肺癌研究协会(IASLC)主办。IASLC世界肺癌大会（WCLC）是世界上最大的致力于肺癌和其他胸部恶性肿瘤的多学科肿瘤学会议，每届都有来自全球100多个国家的7,000多名专业人士参会，共同探讨肺癌和其他胸部恶性肿瘤的最前沿治疗进展。 参会者包括外科医生、医学肿瘤学家、放射肿瘤学家、肺部学家、放射科医生、病理学家、流行病学家、基础研究科学家、护士和相关的卫生专业人员与患者代表。

国际肺癌研究协会(IASLC)是唯一致力于研究和根治肺癌和其他胸部恶性肿瘤的全球性组织，自1974年成立以来，其会员人数已增长到8,000多名，由来自各个学科和100多个国家/地区的肺癌和胸部肿瘤专家组成。IASLC在肺癌的病因学、流行病学、预防、诊断、治疗以及所有与肺癌相关的领域开展深入研究；通过主办全球会议、资助前沿研究、为IASLC成员、医学界和公众宣提供关于肺癌和其他胸部恶性肿瘤的教育和信息，致力于减轻肺癌对患者、家庭和社会的负担。未经许可禁止复制摘录转载本站任何内容-国际医学会议网（lingyuint.com）.

IASLC 2023 World Conference on Lung Cancer (WCLC2023)
Date: September 9-12, 2023
Venue: Singapore 

Organized by: The International Association for the Study of Lung Cancer (IASLC) 

OVERVIEW
The World Conference on Lung Cancer (WCLC) is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies. More than 7,000 delegates come from more than 100 countries to discuss the latest developments in thoracic malignancy research.

Why attend WCLC 2023?

World's Largest
Join the world's largest international gathering of clinicians, researchers and scientists in the field of lung cancer and thoracic oncology.

Connect & Collaborate
Learn, share knowledge and network with over 5,000 delegates from more than 100 countries.

Exemplary Education
Benefit from wide-ranging and multidisciplinary content consisting of over 300 talks and 1,000+ poster presentations and 20 specialized tracks.

Extensive Resources
Choose from ground-breaking plenaries, experts lectures, research abstracts, as well as several sessions specifically dedicated to nurses, patients and advocates.

摘要征文投稿-重要日期：

点此提交摘要>>>Submit Abstract>>>

Regular Abstract
Definition: Original scientific research that summarizes work done and major research findings.

Required sections for abstract submission:

• Introduction
• Methods
• Results
• Conclusion

Clinical Trials in Progress (eligible for designation as e-poster only)
Definition: Ongoing trials that have not reached pre-specified endpoints for analysis.

Required sections:

• Introduction
• Methods
• Optional sections:
• Results
• Conclusion

Case Report (eligible for designation as e-poster only)
Definition: Detailed report of symptoms, signs, diagnosis, treatment and follow up of an individual patient.

Required sections for abstract submission:

• Introduction
• Methods
• Results
• Conclusion

Late-Breaking Abstract (LBA) Submission
Definition: LBA designation will only be given to prospective randomized studies or original research that have practice changing potential for which data is not available at the time of abstract placeholder submission due to study timelines.

LBA designation is not a means for extending the regular abstract deadline. Any abstract that fails to meet LBA requirements will be designated as a regular abstract and rated based on the information available on the submission deadline.

Submission requirements: Authors of LBA must submit a place holder abstract through the abstract portal by April 14, 2023 (23:59 PST).

Required sections for place holder abstracts:

• Explanation of why the abstract qualifies as late-breaking (including the endpoints for which data will be provided and the date for which the abstract will be updated prior to the LBA final submission deadline on June 16, 2023).
• Introduction
• Methods, including endpoints measured
• Types of analysis and anticipated data reporting
• Results and conclusion will be submitted by June 16, 2023

Review: The Scientific Program Committee will review LBA abstract placeholder applications. Authors of approved LBAs will be notified and instructed on deadlines and the processes for submitting final data by June 16, 2023, the final LBA deadline. LBA abstracts not completed by the June 16, 2023 deadline will be automatically withdrawn and will not be considered for the meeting.

Abstract Submission Guidelines

Review the IASLC Language Guide to review guidelines on the best practices to promote the use of language that respects the dignity of people diagnosed with lung cancer.

Word Limit: 500 words (does not include title and authors) 
Abstracts should be organized in different sections based on the selected abstract type. Please refer to the 'Abstract Type' section on this page for further information. 

Title Word Limit: 125 characters total (including spaces).

Tables: No limit; each table counts as 100 words. 

Images: 2 maximum; each image counts as 100 words. 

Format(s): Upload tables, images and graphs in GIF, JPEG, JPG or PNG format of a minimum of 300 dpi and 100% size. Higher resolution is acceptable and preferred. 

Language: English 

Fee: No submission fee 

Submission Limit: Presenters are limited to 2 oral presentations. 

Number of Co-authors: No limit 

Encore Submission: An abstract that has previously been presented at another meeting will only be considered if there have been significant updates to the abstract. Submitters are required to list any previously presented abstracts in the introduction of the abstract.

Financial disclosure and affiliation information is required for the presenting author. For reference, here is a link to the disclosure form. 

Publication: Authors must agree to allow publication of accepted abstract(s) in the Journal of Thoracic Oncology (JTO) and the conference website. Most abstracts will be published and released prior to the meeting, except for embargoed abstracts which will be posted on the day of presentation. 

Education Awards 
These awards are presented to individuals with high scoring abstracts who meet categorical eligibility criteria and who apply. Applications must be completed by the abstract and education award submission deadline April 14, 2023 (23:59 PST).

Plagiarism Policy 

Definition: Plagiarism encompasses all of following: 

1. Direct: intentionally submitting another person’s words or ideas verbatim as one’s own; 
2. Self-plagiarism: submitting work that has been previously published or presented; 
3. Mosaic plagiarism: stringing together portions of text from other sources; and 
4. Lack of attribution: failing to appropriately identify and cite sources for language or ideas that are incorporated. 

For more information see: Das N, Panjabi M. Plagiarism: Why is it such a big issue for medical writers? Perspect Clin Res. 2011;2(2):67–71. doi:10.4103/2229-3485.80370  

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3121267/  

• Screening: IASLC screens all abstracts using anti-plagiarism software. Abstracts identified as having high levels of plagiarized content will be evaluated by IASLC staff and appropriate actions taken. 
• Penalties for plagiarism may include: Rejection of abstract, and/or author(s) banned from making presentations at IASLC conferences. 

Independence of Educational Activities Policy 

• Employees of ACCME defined ineligible companies are prohibited from presenting educational content for Continuing Medical Education. Consequently, employees of ineligible companies are prohibited from giving presentations during accredited CME sessions (e.g., Presidential and plenary symposia, invited educational sessions) . 
• In situations where the presenting author is an employee of an ineligible company, the abstract will automatically be considered for an e-poster. 
• Presenting authors must be registered for WCLC 2023 independent of an ineligible company, except for employees of ineligible companies, who are allowed to be registered by their employers. 
• Presenting author must control all content. Ineligible companies may not influence scientific content by requiring the use of company slide decks or other materials. Scientific data generated by industry sponsored research is permissible. 
• Content of educational activities must be well-balanced, evidence based and unbiased. Generic names should be used to the extent possible. 
• Ineligible companies/commercial interests may not submit registration materials or fees on behalf of learners, faculty or others attendee types. 

WCLC2023 注册费：

In-Person & Virtual Registration Fees

**Developing Nations: List of countries available at www.iaslc.org/Membership/Developing-Countries-List

***For questions or to confirm eligibility within this category, please contact: advocacy@iaslc.org